Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 8;38(9):2954-2960.
doi: 10.1021/acs.langmuir.1c03434. Epub 2022 Feb 25.

Characterizing Aptamers with Reconfigurable Chiral Plasmonic Assemblies

Affiliations

Characterizing Aptamers with Reconfigurable Chiral Plasmonic Assemblies

Yike Huang et al. Langmuir. .

Abstract

Aptamers have emerged as versatile affinity ligands and as promising alternatives to protein antibodies. However, the inconsistency in the reported affinities and specificities of aptamers has greatly hindered the development of aptamer-based applications. Herein, we present a strategy to characterize aptamers by using DNA origami-based chiral plasmonic assemblies as reporters and establishing a competitive hybridization reaction-based thermodynamic model. We demonstrate the characterization of several DNA aptamers, including aptamers for small molecules and macromolecules, as well as aptamers with high and low affinities. The presented characterization scheme can be readily adapted to a wide selection of aptamers. We anticipate that our approach will advance the development of aptamer-based applications by enabling reliable and reproducible characterization of aptamers.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing financial interest(s): A.K. and Y.H. are listed as inventors in submitted provisional patent application (FIPT202100000003522) covering characterization of nucleic acid-based affinity ligands using DNA origami-based chiral assemblies. The remaining authors declare no competing financial interests.

Figures

Figure 1
Figure 1
(A) Schematics of DNA origami-based chiral plasmonic probes. The aptamer and a partially complementary strand are incorporated into the probe as an analyte responsive lock. The hybridized state of the two strands corresponds to the closed configuration of the probe (I); the separation of the strands results in open probe configurations (II, III). (B) Configurations of aptamer locks with varied lengths of hybridization (n) between the aptamer and the complementary strand. The hybridization length of n = 0 bp corresponds to the open lock. Increasing n shifts the equilibrium toward the hybridized state of the lock and the closed configuration of the chiral probes. (C) Description of the system in terms of chemical reactions: A, B, and C are the aptamer, analyte, and complementary strand, respectively; ΔG° and KD are the corresponding Gibbs free energy and dissociation constants, respectively, with KD2 being the aptamer–analyte dissociation constant of interest. (D) Brief overview of data analysis for the determination of KD2. The probes with the aptamer and partially complementary strands of different lengths are incubated with or without the analyte. With the parameters obtained from the calibration experiments and computational prediction tools, KD2 is calculated by measuring the amplitude changes of the CD spectra in the presence and absence of the analyte.
Figure 2
Figure 2
(A) To obtain the coefficient ε between the predicted (ΔGtheory°) and real (ΔGr°) Gibbs free energies, the hybridization length (n) between the aptamer and the complementary strand is varied from 8 to 14 bp (n = {8–14}). (B) Normalized CD spectra of the probes with different hybridization lengths (n). (C) Dependence of ΔGtheory°(n) on the normalized CD signal at 620 nm is used to calculate ε. (D) To obtain the local concentration of A and C strands (a0), n is varied between 10 and 13 bp (n = {10–13}). A competitor DNA strand (10 nt) is used as an analyte. (E) By varying n, the dependence of β on KD1 is used to calculate a0.
Figure 3
Figure 3
(A) Hybridization of complementary strands to the 5′ or 3′ end of the ATP aptamer with hybridization lengths varied between 9 and 12 bp (n = {9–12}). (B,C) Dependence of βn on KD1(n) with the complementary strand hybridizing at the 5′ (B) or 3′ (C) end of the ATP aptamer. KD2ATP values of 5.71 ± 0.865 μM (B) and 117 ± 62.8 μM (C) were obtained from the fitting. (D) Dependence of β on the ATP concentration (b0) produced KD2ATP values of 4.54 ± 0.580 μM. (E) Specificity characterization of the ATP aptamer (see Figure S12 for CD spectra).
Figure 4
Figure 4
(A,B) Dependence of βn on KD1(n) with complementary strand hybridizing at the 5′ (A) or 3′ (B) of the glucose aptamer.KD2glu values of 5.57 ± 0.436 mM (A) and 110 ± 20.0 mM (B) were obtained from the fitting. (C) Specificity characterization of the glucose aptamer (see Figure S13 for CD spectra). (D,E) Dependence of βn on KD1(n) with the complementary strand hybridizing at 5′ (D) or 3′ (E) of the thrombin aptamer.KD2thr values of 235 ± 24.1 nM (D) and 46.7 ± 7.27 nM (E) were obtained from the fitting. (F) Specificity characterization of the thrombin aptamer (see Figure S14 for CD spectra).

Similar articles

Cited by

References

    1. Cho E. J.; Lee J.-W.; Ellington A. D. Applications of Aptamers as Sensors. Annu. Rev. Anal. Chem. 2009, 2, 241–264. 10.1146/annurev.anchem.1.031207.112851. - DOI - PubMed
    1. Dunn M. R.; Jimenez R. M.; Chaput J. C. Analysis of Aptamer Discovery and Technology. Nat. Rev. Chem. 2017, 1, 1–16. 10.1038/s41570-017-0076. - DOI
    1. Ni S.; Zhuo Z.; Pan Y.; Yu Y.; Li F.; Liu J.; Wang L.; Wu X.; Li D.; Wan Y.; Zhang L.; Yang Z.; Zhang B.-T.; Lu A.; Zhang G. Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications. ACS Appl. Mater. Interfaces 2021, 13, 9500–9519. 10.1021/acsami.0c05750. - DOI - PubMed
    1. Keefe A. D.; Pai S.; Ellington A. Aptamers as Therapeutics. Nat. Rev. Drug Discovery 2010, 9, 537–550. 10.1038/nrd3141. - DOI - PMC - PubMed
    1. Panigaj M.; Johnson M. B.; Ke W.; McMillan J.; Goncharova E. A.; Chandler M.; Afonin K. A. Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology. ACS Nano 2019, 13, 12301–12321. 10.1021/acsnano.9b06522. - DOI - PMC - PubMed

Publication types